Although several reports have demonstrated that BCR-ABL/JAK2 inhibits CML cells including ABL TKI-resistant cells [21,22], it is not completely known whether JAK2 is involved in CML stem cell survival mediated by cytokines in the presence of ABL TKI. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.